Skip to main content
Glama

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. Changed3 schema fields changed
    • changedInput schema / properties / type / description
      Previous value: -"Entity type. v1 supports \"company\"."New value: +"Entity type: \"company\" or \"drug\"."
    • changedInput schema / properties / type / enum
      Previous value: -[
      -  "company"
      -]New value: +[
      +  "company",
      +  "drug"
      +]
    • changedInput schema / properties / value / description
      Previous value: -"Ticker, CIK, or company name (e.g., \"AAPL\", \"0000320193\", \"Apple\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."
  3. Added

TDQS

A4.8/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already mark this read-only, idempotent, and non-destructive, and the description adds substantial behavioral detail beyond that: graceful degradation of LEI/FIGI enrichment, internal cascading lookups, ambiguity handling via figi_candidates, and explicit reporting of unresolved identifiers. No contradiction with annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness5/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long but well-structured and dense with useful information: example queries, supported types, input formats, edge cases, and failure behavior. Each section earns its place given the tool's complexity, and the key guidance is front-loaded.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

There is no output schema, but the description documents the important return semantics: canonical identifiers, source labels, unresolved fields, and figi_candidates. It also covers supported types, input formats, enrichment degradation, and ownership relationships, making it complete enough for an agent to invoke correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema description coverage is 100%, but the description adds high-value semantics beyond the schema: accepted value forms (ticker, CIK, ISIN, name), ISIN-to-LEI legal entity resolution, the exact-issuer-name guidance for bonds, and the figi_candidates disambiguation behavior.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with concrete user phrasings and states a clear mission: resolve a user-spoken name into canonical identifiers other tools require as input. It also makes the distinction from sibling tools like entity_profile and compare_entities by focusing on ID resolution rather than profiling or comparison.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly says 'Use FIRST whenever you have a name but need an ID' and scopes usage by type (company or drug). It provides clear context for when to invoke, though it does not explicitly name sibling alternatives or when not to use this tool.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.5/5.0
Disambiguation2/5

Several tools overlap heavily: ask_pipeworx and ask_pipeworx_beta are explicitly identical, ask_pipeworx_grounded and deep_research both route queries to the same 5,529 tools, and ai_visibility_check vs scan_competitor_ai_presence are near-duplicates. Only the small ga_* subset is clearly distinct.

Naming Consistency2/5

Conventions are mixed: GA tools use a ga_ prefix, but the majority use arbitrary names like ask_pipeworx, deep_research, remember, scan_dependency, and polymarket_arbitrage. No consistent verb_noun pattern across the set.

Tool Count2/5

35 tools is heavy, and the vast majority (31) are unrelated Pipeworx utilities rather than Google Analytics functionality. Only 4 tools actually serve the stated GA purpose, making the count inappropriate for the server name.

Completeness2/5

For Google Analytics, the surface is minimal: list properties, metadata, realtime, and run report—no property management, user management, or data mutation. As a Pipeworx toolkit it's broad but lacks full lifecycle coverage for any single domain.